CClinicalTrials.gg
Sign In
RecruitingNCT01731353FungiScopeUpdated Dec 5, 2023

FungiScope - A Global Emerging Fungal Infection Registry

An observational study in Invasive Fungal Disease, sponsored by University of Cologne. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by University of Cologne · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Study summary

The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.

Read the detailed description

The specific objectives are:

  1. To determine the fungal species causing invasive fungal infection in different parts of the world.
  2. To determine the clinical pattern of disease and document procedures performed for confirmation of the diagnosis.
  3. To describe the therapeutic regimens used and their efficacy.
  4. To share clinical isolates among the contributors of Fungiscope.
  5. To develop molecular biology tools for identification of strains in histopathologically proven invasive fungal infection.
02

Conditions studied

  • Invasive Fungal Disease

Keywords

  • invasive fungal infection
  • Web-based registry
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

University of Cologne is the lead sponsor of 199 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Invasive infections caused by emerging fungi

Inclusion criteria

  • Cultural, histopathological, antigen or DNA evidence of invasive fungal infection

Exclusion criteria

Exclusion Criteria:

  • Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci
  • Endemic fungal infection such as coccidioidomycosis or histoplasmosis
  • Colonisation or other non-invasive infection
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Emerging fungal infections

    Web-based registry of invasive infections by emerging fungi

06

What researchers measure

Primary outcomes

  1. Treatment efficacy of emerging fungal infections

    failure, stable disease, partial response or complete response

    Time frame: At 90 days from diagnosis

07

Study locations

1 of 1 sites recruiting
  • University Hospital Cologne
    Cologne, NRW 50937, Germany
    Recruiting
08

References and documents

Publications

  • Koehler P, von Stillfried S, Garcia Borrega J, Fuchs F, Salmanton-Garcia J, Pult F, Boll B, Eichenauer DA, Shimabukuro-Vornhagen A, Kurzai O, Boor P, Kochanek M, Cornely OA. Aspergillus tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study. Eur Respir J. 2022 May 5;59(5):2103142. doi: 10.1183/13993003.03142-2021. Print 2022 May. PubMed 35144992 ↗
  • Hassler A, Lieb A, Seidel D, Cesaro S, Greil J, Klimko N, Khostelidi S, Solopova G, Ogunc D, Duran Graeff L, Cornely OA, Vehreschild MJ, Lehrnbecher T. Disseminated Fusariosis in Immunocompromised Children-Analysis of Recent Cases Identified in the Global Fungiscope Registry. Pediatr Infect Dis J. 2017 Feb;36(2):230-231. doi: 10.1097/INF.0000000000001396. PubMed 27846057 ↗
  • Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9. PubMed 26969258 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01731353
Lead sponsor
University of Cologne
Collaborators
Pfizer, Basilea Pharmaceutica, Cidara Therapeutics Inc., F2G Biotech GmbH, Matinas Biopharma, Inc
Responsible party
Oliver Cornely, MD (Dr. med., University of Cologne) — Principal investigator
First posted
Nov 21, 2012
Start date
Mar 2003
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 5, 2023

Study contacts

Oliver A Cornely, Prof.
Contact
oliver.cornely@uk-koeln.de
+49 221 478 ext. 6494
Oliver A. Cornely, Professor
principal investigator · University Hospital of Cologne

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infections→

Other studies from this sponsor

University of Cologne

Start the discussion